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Abstract: Duchenne muscular dystrophy (DMD) is the most common childhood neuromuscular
disorder. It is caused by mutations in the DMD gene that disrupt the open reading frame (ORF)
preventing the production of functional dystrophin protein. The loss of dystrophin ultimately leads
to the degeneration of muscle fibres, progressive weakness and premature death. Antisense
oligonucleotides (AOs) targeted to splicing elements within DMD pre-mRNA can induce the skipping
of targeted exons, restoring the ORF and the consequent production of a shorter but functional
dystrophin protein. This approach may lead to an effective disease modifying treatment for DMD
and progress towards clinical application has been rapid. Less than a decade has passed between the
first studies published in 1998 describing the use of AOs to modify the DMD gene in mice and the
results of the first intramuscular proof of concept clinical trials. Whilst phase II and III trials are now
underway, the heterogeneity of DMD mutations, efficient systemic delivery and targeting of AOs to
cardiac muscle remain significant challenges. Here we review the current status of AO-mediated
therapy for DMD, discussing the pre-clinical, clinical and regulatory hurdles and their possible
solutions to expedite the translation of AO-mediated exon skipping therapy to clinic.
Keywords: Antisense oligonucleotides, clinical trials, duchenne muscular dystrophy, becker
muscular dystrophy, dystrophin, exon skipping, RNA therapy
Introduction
Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is a
fatal, X-linked, neuromuscular disorder
that affects 1 in 3,500 newborn boys.
Patients are typically diagnosed as
toddlers; they develop progressive muscle
weakness and cardiomyopathy and lose
the ability to walk by their early teens.
Unless appropriate standards of care
(including non-invasive ventilation,
glucocorticoid and cardio-protective
treatment) are implemented, premature
death by cardiac or respiratory failure
occurs in the second decade of life (1-3).
DMD is caused by mutations in the DMD
gene that disrupt the open reading frame
(ORF) thus aborting the full translation of
its protein product, dystrophin (4, 5). The
DMD gene comprises 79 exons and the
majority (~65%) of mutations responsible
for DMD are out-of-frame deletions,
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although duplications (~10%), small
mutations including non-sense and splice
site changes (~22%) and deep intronic
mutations (~3%) are also documented (6,
7). Some DMD deletions are more
frequent than others and the gene has
two deletion hotspots (6): the most
commonly mutated region is exons 45–55
followed by exons 2–19.
Dystrophin is located underneath the
sarcolemma and connects the sub-
sarcolemmal cytoskeleton to the
extracellular matrix by binding N-
terminally to cytoskeletal F-actin and to
β–dystroglycan via a cysteine rich domain 
near the C-terminus (8) (Top panel, Figure
1). It contains four main functional units:
an N-terminus, a central rod domain, a
cysteine rich domain and a C-terminal
domain. The central rod domain consists
of 24 spectrin-like repeats and four hinge
domains (9). Dystrophin interacts with
actin at both its N-terminus and via
spectrin-like repeats 11-17; the C-
terminus has also recently been shown to
allosterically affect actin binding (10). The
cysteine rich domain binds to β-
dystroglycan (BDG) (11-15) and the C-
terminal domain is required for binding to
syntrophin (16) and dystrobrevin (17).
These and other sarcolemmal proteins
such as the sarcoglycans are components
of the dystrophin associated glycoprotein
complex (DGC). Dystrophin and the DGC
play an important role in stabilising the
muscle fibre against the mechanical forces
of muscle contraction by providing a
shock-absorbing connection between the
cytoskeleton and the extracellular matrix.
Loss of dystrophin leads to disruption of
the complex, which results in
inflammation, increased intracellular
calcium influx, muscle degeneration and
replacement of muscle with adipo-fibrous
tissue (4). In addition, dystrophin plays a
role in signalling and is associated with
members of the stretch-activated calcium
channels; their mislocalisation and
dysfunction in dystrophic muscle
contributes to disease progression (18).
Spectrin repeats 16 and 17 within the
central rod domain, encoded by exons 42–
45, are also required for binding to
neuronal nitric oxide synthase (nNOS) (11,
12, 19). nNOS regulates the blood flow in
skeletal muscle (20); disruption of this
pathway may contribute to DMD
pathogenesis by inducing paradoxical
vasoconstriction during exercise (21).
Naturally-occurring dystrophin positive
“revertant fibres” (isolated or less
commonly small clusters of fibres strongly
positive for dystrophin) and “traces”
(fibres expressing very low levels of
dystrophin at the sarcolemma) occur in
more than 50% of the muscle biopsies of
DMD patients (22). Revertant fibres
represent a very small percentage of the
total fibres, in which somatic mutations or
stochastic alternative splicing events of
the dystrophin pre-mRNA lead to exon
skipping, the restoration of the ORF and
consequent expression of dystrophin (23,
24). Revertant dystrophins are correctly
localised to the sarcolemma and associate
with other DGC proteins, suggesting a
retained function (25, 26). Revertant
fibres have been well characterised in the
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mouse model of DMD, the mdx mouse
(24, 27, 28). Whilst traces have not been
described in the mdx mouse, they are
present in approximately a third of DMD
patients (22) and may represent up to
25% of the total muscle fibres (29). The
molecular mechanism of trace dystrophin
expression remains to be elucidated, but
it is thought to be at least in part different
from that of revertant fibres. For example,
traces can express different dystrophin
epitopes than the surrounding revertant
fibres (22).
Becker muscular dystrophy
Mutations in the DMD gene are also
responsible for a milder disorder, Becker
muscular dystrophy (BMD), a disease with
an extremely variable spectrum of
severity ranging from patients with
walking difficulties in their late teens or
early twenties, to the majority of
individuals in whom ambulation is
preserved into late adulthood and who
have an essentially normal lifespan (30).
DMD and BMD mutations differentially
affect the DMD gene: in DMD the
mutations disrupt the reading frame,
while mutations that cause BMD maintain
the ORF (31, 32) leading to the production
of an internally deleted dystrophin
protein. The size of the deletion does not
correlate with the severity of the disease,
as long as the reading frame rule is
maintained (33-40), and provided crucial
domains of dystrophin such as the β-
dystroglycan binding site are not removed
by the deletion. While the central and
distal rod domain is less vital for function
(35), (some patients missing these
domains only have very mild disease
manifestations such as myalgia and
muscle cramps, and mild weakness), in
frame deletions that affect the binding of
dystrophin to other proteins such as
cytoskeletal actin or β-dystroglycan result 
in a severe phenotype (41, 42).
The existence of revertant fibres in DMD
and the occurrence of mildly affected
BMD individuals with in-frame deletions
suggest that it is feasible to modify
splicing by exon skipping (Figure 1) and
induce the production of functional
dystrophin in DMD patients, as long as
crucial domains of dystrophin are not
disrupted. Artificially restoring the ORF in
this way is thus an attractive therapeutic
strategy for DMD, as approximately 70%
of DMD patients have mutations
amenable to exon skipping (43).
Figure1 Exon skipping principle. (Next page) Upper panel:
Schematic representation of dystrophin mRNA (in-frame exons
are represented as square boxes, out-of-frame exons round or
arrow boxes). Normal splicing of these exons produces
dystrophin protein (pictured immediately below) retaining
functional protein-binding domains and correctly localised to
the sarcolemma (see section of control muscle stained with
anti-dystrophin antibody Dys2). Lower panel: representation of
dystrophin pre-mRNA highlighting the differences in splicing
between a Del48-50 DMD patient (left) and a Del48-51BMD
patient (right). The DMD deletion disrupts the open reading
frame (ORFs) which results in unstable mRNA and the absence
of functional dystrophin protein in muscle sections. In the BMD
patient the deletion maintains the ORF and generates the
production of an internally deleted dystrophin isoform that
retains the critical amino and carboxyl terminals and Cysteine -
rich domains. The ORF can be corrected by forced skipping of
exon 51 by directing antisense oligonucleotides to sequences
within exon 51 or to neighbouring intronic regions. Exon 51
skipping restores the ORF, generating a dystrophin equivalent
to that of the BMD patient. Insert table: Theoretical
applicability of single exon skipping in a series of DMD
deletions.
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Table 1 Comparison between the two leading candidates for exon 51 skipping.SC = subcutaneous; IV = intravenous; IM =
intramuscular
PRO051/GSK2402968 AVI-4658/ETEPLIRSEN
Company Prosensa/GlaxoSmithKline AVI-BioPharma
Type
2’O-methyl phosphorothioate
(2'OMe)
Phosphorodiamidate
morpholino oligomer (PMO)
Backbone structure
Size and sequence
20 mer
(TCAAGGAAGATGGCATTTCT)
30 mer
(CTCCAACATCAAGGAAGATG
GCATTTCTAG)
Delivery SC IV
Plasma protein binding
Backbone binds to serum
proteins No
Serum half life <4 h to 28 days (44, 45) 1.62 to 3.60 hours (46)
Max non-toxic dose in patients:
Proteinuria seen in all patients
at 6mg/kg (44) Not reached (46)
Max tested non-toxic dose in
mice: ?
960mg/kg (47)
Max tested non-toxic dose in
primates: ?
320mg/kg (47)
Orphan drug Yes Yes
SYSTEMIC TRIAL REPORTED RESULTS*
Total number of patients 12 (44) 19 (46)
Pre-
treatment
Post-
treatment
Pre-
treatment Post-treatment
Maximum reported
dystrophin-positive fibres Not done 100% 5% 55%
Maximum dystrophin signal
intensity to control muscles by
immunofluorescence Not done 15.6% 11% 27%
Maximum dystrophin protein
level to control muscles by
western blotting Not done Not done 5% 18%
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Antisense oligonucleotide-mediated exon
skipping
Antisense oligonucleotides (AOs) targeted
to splicing elements represent the most
clinically advanced therapeutic tools
developed to induce dystrophin exon
skipping (48, 49). AOs are typically 20–30
nucleotides in length, and complementary
in sequence to regions of the pre-mRNA
transcript (50). While several AO
chemistries exist, the two AOs in clinical
development for DMD are 2’O-methyl
phoshophorothioate oligoribonucleotide
(2’OMe) and phosphorodiamidate
morpholino oligomers (PMO), (Table 1)
and (51, 52) for a detailed review. 2’OMe
AOs bind to albumin, showing high plasma
concentrations and long half-lives (45);
this might be an advantage as PK studies
indicate a longer persistence in blood
compared to PMO (up to 28 days as
opposed to less than 4 hours); however
binding to protein has been shown to
trigger activation of the immune system,
anaphylaxis, hypotension, or
antiarrhythmic effects in preclinical and
clinical studies (53). PMOs are not
metabolised and are resistant to
endonucleases (54); they are rapidly
eliminated from the bloodstream as they
are uncharged and do not bind serum
proteins, which is likely why they have not
been associated with the side effects
mentioned for the 2OMe clinical studies.
Both AOs have proven successful in pre-
clinical mouse models (55-58) and as far
as the PMO is concerned, also the more
severe dog model (59), in which systemic
delivery has resulted in dystrophin protein
production (60, 61) and physiological
improvement (58) of skeletal muscle.
Clinical progress
Both PMO (AVI-4658/eteplirsen) and
2’OMe (GSK-2402968) AOs targeting exon
51 (which will restore the ORF in the
largest group of DMD patients (13%))
have proven successful at inducing local
dystrophin expression in pivotal proof-of-
concept intramuscular clinical trials (62,
63). Recently, systemic studies using the
two different AO chemistries have been
completed (Table 2) (44, 46),
demonstrating that AO therapy for DMD is
indeed safe and well tolerated with no
significant drug-related adverse events.
Both studies reported significant
dystrophin restoration in a dose-
dependent manner as determined by
western blotting and
immunohistochemistry, with levels of
dystrophin approaching 20% of normal
levels in the PMO study.
The outcome of randomised placebo-
controlled studies of both eteplirsen and
GSK-2402968 is expected in 2012 and
further studies are planned. Table 2
summarises the design of both completed
and ongoing ClinicalTrials.gov registered
studies correct at the time of publication.
In addition, AOs for exons 45, 52, 53 and
55 are undergoing pre-clinical
development by GSK whilst AVI
BioPharma is developing PMOs targeting
exons 45, 50 and 53. Plans to extend trials
of systemically-delivered AOs to non-
ambulant boys are also underway for
exon 51 skippable patients (both with
eteplirsen and GSK2402968).
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Completed Ongoing
Intra-muscular Systemic Systemic
Study drug AVI-4658
(Eteplirsen)
PRO051 (GSK-
2402968)
AVI-4658
(Eteplirsen)
PRO051 (GSK-
2402968)
AVI-4658
(Eteplirsen)
PRO051 (GSK-
2402968)
PRO051 (GSK-
2402968)
PRO051 (GSK-
2402968)
PRO051 (GSK-
2402968)
PRO051 (GSK-
2402968)
PRO044
ClinicalTrials.gov
identifier
NCT00159250 Netherlands
trial register:
NTR712
NCT00844597 EudraCT
number: 2007-
004819-54
NCT01396239 NCT01153932 NCT01462292 NCT01254019 NCT01128855 NCT01451281
(parent study:
NCT01462292)
NCT01037309
Phase I/II I/II I/II I/II II II II III I n/a I/II
Study design Single-blind,
placebo-
controlled, dose-
escalation
Single dose open-label,
dose-escalation
open-label,
dose-escalation
Randomised,
double-blind,
placebo-
controlled,
multiple Dose
Randomised,
double blind,
placebo
controlled
Randomised,
double blind
Randomised,
double blind
Double-blind,
escalating dose,
randomized,
placebo-controlled
n/a Non-randomised,
open label
Chemistry PMO 2’OMe PMO 2’OMe PMO 2’OMe 2’OMe 2’OMe 2’OMe 2’OMe 2’OMe
Number of patients 7 4 19 12 12 54 54 180 32 85 18
Target exon 51 51 51 51 51 51 51 51 51 51 44
Ambulant/Non
Ambulant
Ambulant Ambulant Ambulant Ambulant Ambulant Ambulant Ambulant Ambulant Non-ambulant Ambulant Ambulant
Delivery IM (EDB) IM (TA) IV Subcutaneous IV Sub-cutaneous Sub-cutaneous Sub-cutaneous Subcutaneous Sub-cutaneous Subcutaneous &
I.V (1.5, 5mg/kg)
Dose 0.09 and 0.9 mg 0.8 mg 0.5, 1, 2, 4, 10,
and 20 mg/kg
body weight
0.5, 2, 4 and 6
mg/kg body
weight
30, 50 mg/kg
body weight
6 mg/kg body
weight
3, 6 mg/kg body
weight
6 mg/kg body
weight
3, 6, 9 & 12 mg/kg
body weight
3, 6 mg/kg body
weight
0.5, 1.5, 5, 8, 10,
12 mg/kg body
weight
Frequency of
administration
Single Single Weekly Weekly Weekly Weekly & twice
weekly
Weekly Weekly Single Weekly Weekly
Duration 3-4 weeks 4 weeks 12 weeks 12 weeks 24 weeks 24-48 weeks 24 weeks 1 year 5 weeks 24 weeks 5 weeks
Primary outcome
measure
Safety Adverse events Safety Safety Dystrophin
positive fibers
Efficacy 6 minute walk
distance test
Efficacy Pharmacokinetics MRI changes in
skeletal muscle
Safety,
tolerability,
pharmacokinetics
& dystrophin
expression
Start Date October 2007 2006 January 2009 2008 July 2011 September
2010
October 2011 December 2010 July 2010 September
2011
December 2009
Completion date March 2009 2007 December 2010 2011 June 2012
(estimated)
September
2012
(estimated)
April 2013
(estimated)
December 2012
(estimated)
November 2011 2012
(estimated)
December 2012
(estimated)
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(Previous page) Table 2 Summary of completed
and on-going exon skipping clinical trials for DMD
IV = intravenous; IM = intramuscular
Current challenges
In-vitro optimisation of novel AOs
Systematic screening for AO targets has
already identified targets for most of the
79 dystrophin exons (64-66), but there is
variability in the processes used to design
and evaluate target AOs. For example,
variations in the cell type for in vitro
studies, transfection reagents, time of
evaluation and quantification of skipped
product (64, 67-69) make inter-study
comparisons difficult. Despite the fact
that bioinformatic tools (70-73) can
provide optimal target areas for AO
binding, and help rank AO sequences
according to their predicted bioactivity
(43, 65), empirical analysis in-vitro is
always necessary to confirm the suitability
of the sequence (69). Importantly,
restoration of dystrophin expression can
only be shown in differentiated myotubes
derived from patients’ cells as dystrophin
is only expressed in myotubes and not in
myoblasts. Ideally, cells from several
patients holding different amenable
deletions should be used to test the
efficacy of an AO, as the intronic
breakpoints differ between patients and
might affect splicing efficiency (74).
Primary myoblasts derived from DMD
muscle biopsies can be difficult to expand
in culture (75, 76) and the extent of
myogenic differentiation of DMD
myoblasts is often low (77, 78). Similar
levels of differentiation would be required
for quantitative comparison of the
efficacy of the same AO on cells from
patients with different mutations. In
order to improve the proliferative capacity
of human myoblasts so that large
numbers of cells are available for replicate
experiments, techniques to immortalise
human myoblasts have been developed
(79).
A less invasive alternative to the use of
muscle biopsies to prepare satellite cell-
derived myoblasts, are fibroblasts
prepared from a skin biopsy. Fibroblasts
can be induced to differentiate into
myotubes by forced expression of the
myogenic regulatory factor MyoD (80).
However, the levels of DMD transcripts in
myotubes derived from fibroblasts can be
low and the variable extent of myogenic
differentiation should be controlled for in
comparative experiments.Transgenic
mice, harboring the entire human DMD
locus, may be used to test antisense
oligonucleotides (64, 67, 81-83).
However, these mice also carry the mouse
dystrophin gene and have no skeletal
muscle pathology.
Outcome measures
A validated set of clinical outcome
measures for ambulant DMD patients is in
use in the ongoing phase II and III clinical
trials. Future trials on non-ambulant
patients pose a further challenge where
robust measurements of upper limb
strength and function in late disease stage
are required. While clinical outcome
measures are needed to demonstrate
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functional improvement, biochemical
outcome measures (BOMs) are required
to monitor AO efficacy. However, critical
differences in the methodology used
between the different research centres
are of concern. Standardised BOMs are
essential in order to reliably compare the
efficacy of the different chemistries and
dosing regimens. Specifically, the most
reliable methods for quantification of
both exon skipping and dystrophin
restoration must now be established
through initiatives such as the TREAT-
NMD registry of outcome measures for
neuromuscular disorders
(www.researchrom.com/) and from on-
going international collaborative studies
aiming to cross-validate standard
operating procedures. The outcomes of
these should be the standardisation of
methodology across centres that could be
presented to regulatory authorities as the
preferred BOMs in future clinical trials.
The efficacy of exon skipping is measured
at both the RNA and protein level. Nested
RT-PCR is traditionally used to assess and
quantify (semi-quantitatively) AO efficacy
at the RNA level (84, 85). To detect
transcripts using this method, it is
necessary to use up to 70 PCR cycles after
which linearity is lost and it is therefore
not possible to accurately quantify the
percentage of exon skipping. Thus several
quantitative methods are currently in
development such as qRT-PCR using highly
specific TaqMan assays for skipped and
total dystrophin targets. The advent of
digital PCR and micro fluidic technology
enables the high throughput analysis of
patient RNA. For example, exon skipping
could be assessed by measuring changes
in mRNA decay pre and post treatment
using TaqMan assays that cover all 79
dystrophin exons. Such a platform, the
FluiDMD, has recently been described
which simultaneously analyses 85 TaqMan
assays recognising 76 out of 78 DMD exon
junctions (86).
As the aim of AO-mediated exon skipping
is to restore dystrophin production,
reliable methods to quantify dystrophin
expression are vital. The presence of
dystrophin traces and revertant fibres in
DMD muscles (22) makes it essential to
compare treated muscles with a pre-
treatment biopsy of the same patient, in
order to accurately distinguish and
quantify AO-mediated dystrophin protein
production (87). The two most commonly
used methods are western blotting and
immunostaining (46, 87, 88).
Consideration should be given to the
antibodies to be used, which must be
sensitive, specific and have an epitope
appropriate for the dystrophin exons
retained following exon skipping.
As muscle biopsies are invasive and
sample a single muscle, there are
limitations in their use to monitor
response to therapy and efforts are being
made to identify non-invasive biomarkers
to monitor DMD disease progression.
Studies aimed at validating the role of
magnetic resonance imaging (89) and
spectroscopy as well as serum or urine
biomarkers such as small non coding RNAs
(such as miRNA) are currently underway
both in animal models and in clinical
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studies; it is hoped that these will reduce
the need for muscle biopsies (90).
Functionality of the de novo dystrophin
protein
Whilst the primary outcome measure of
the completed systemic trials was clinical
safety, the GSK-2402968 study also
reported a modest improvement in the 6-
minute walk test which is encouraging
(44). From a biochemical perspective, data
from both the intramuscular and systemic
eteplirsen trials further indicate that the
internally deleted dystrophins generated
by exon skipping in different patients are
indeed functional, as they led to the
restoration of proteins of the DGC (46,
91). Additional evidence of functional
improvement is provided by a reduction in
cytotoxic T cells within treated muscle
biopsies (46); this is promising considering
that the pre-symptomatic induction of
inflammatory cascades and the invasion of
muscle by immune cells is one of the
earliest pathways induced in dystrophin
deficient muscle and is thought contribute
to DMD pathology (92, 93). However, the
possibility of an immunological reaction
both against revertant and novel
dystrophin epitopes remains a possibility
(94) and presents a new issue to address
in future clinical trials that will require the
assessment of any pre-existing
immunological response to dystrophin
epitopes in patients prior to their
inclusion in a clinical trial, as well as any
post-treatment response to the newly-
generated dystrophin protein (94).
Some mild or asymptomatic BMD patients
naturally express the dystrophin proteins
that we aim to produce by exon skipping
(32). A recent study correlated dystrophin
and dystrophin-associated protein
expression with disease severity in a
cohort of BMD patients (26). The amount
of dystrophin, nNOS and BDG correlated
to clinical severity and BMD patients with
deletions equivalent to those created by
exon 51 skipping have higher dystrophin
levels than either those with large multi-
exon deletions, or those harbouring exon
53 skippable deletions (26). These findings
demonstrate the therapeutic potential of
the protein that will be generated by exon
51 skipping trials whilst the functionality
of other dystrophins, especially those with
larger internal deletions, is less clear (43,
95-97).
Variability of response
The completed AO-mediated exon
skipping clinical trials have revealed a high
degree of variability in patient response,
even between patients harbouring the
same deletions (46). These findings
suggest that the variability is unlikely to
be due to inter-patient differences in
stability of the resultant protein,
immunological response, or the
pharmacodynamics of the PMO (46).
However, it has been suggested (46) that
differences in the genetic background,
such as intronic deletion breakpoints,
differences in the efficiencies of mRNA
splicing, or differences in the vascular
access of the AO to individual muscles
may contribute to the variable response.
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An important future goal must be to
understand the mechanisms behind this
variability and why some patients respond
better to treatment than others.
Interestingly studies in the mdx mouse
with both PMO and 2’OMe and in the
GRMD dog using PMO have identified
similar variability in response, even in the
same animal, when different muscles
were studied (61, 98-100). This- indirectly-
points towards stochastic events involved
in delivering the AO to skeletal muscle
rather than a genetic difference, although
more studies are needed to elucidate the
mechanism responsible for the observed
variability and whether this variability may
be reduced after long-term treatment as
indicated by studies on the mdx mouse
(98).
Next generation AOs
Although extremely high-doses of PMO
without modification can induce
dystrophin rescue in mdx cardiac muscle
(101), unmodified AOs are largely
unsuccessful at inducing exon skipping in
the heart and they do not cross the blood
brain barrier (56, 58). This is important
given that cardiac complications are
observed in up to 90% of DMD patients
(102) and that 1/3 of DMD patients suffer
cognitive impairment related to the
deficiency of dystrophin in the brain (103,
104). One approach to improve AO
targeting to cardiac muscle is the direct
conjugation of cell penetrating peptides to
AOs which improves AO delivery to
skeletal (105-112) and cardiac mdx mouse
muscles (111, 113-115); however the
toxicology of these conjugates has yet to
be ascertained. The fact that the
dystrophin protein is thought to have a
long half-life should increase the
possibility of achieving and maintaining
therapeutically-relevant dystrophin
protein levels with weekly or longer
dosing intervals
Regulatory hurdles
The regulatory process for developing AOs
to skip other dystrophin exons is at
present cumbersome as each new AO is
considered a novel drug and requires the
full battery of genotoxicity, rodent and
non-human primate acute and chronic
toxicity studies (reviewed in (116)). This
stringent assessment of safety is of
paramount importance, considering that
there has been little experience in dosing
individuals with AOs at high doses and for
durations exceeding 1 year (and
theoretically for a lifelong therapy).
Nevertheless, the current studies have not
reported severe drug related adverse
events; in addition most of the toxicity
related to AOs derives not from the
individual sequences but from the chronic
chemical load which is therefore largely
backbone but not sequence specific. It is
hoped that the positive clinical experience
gained from the exon 51 skipping studies
and hopefully also from other exons will
allow us to gather additional information
so that in the future these compounds
could obtain class approval and follow a
more informed and streamlined
regulatory process.
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Conclusions
Preclinical and clinical studies using two
different chemistries have demonstrated
the potential of antisense oligonucleotide-
mediated DMD exon skipping to modify
the progression of DMD. If progress in
this field continues at the pace of the last
decade, treatment for common DMD
mutations may soon be feasible. If no
sequence-specific toxic effect is found,
treatment of rare mutations could follow
as regulatory hurdles are overcome.
Furthermore this approach could treat
nonsense mutations or other frame-
shifting mutations located in in-frame
exons that could be removed by skipping
a single exon. The clinical development of
next generation AOs that effectively
target cardiac as well as skeletal muscle
will provide a significant quality of life
improvement for patients.
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